The ‘Parenting Advantage’ and Innovation Processes in the Multinational Firm: Does Top Management Mess Things Up?

Mats Forsgren

Chapter 4 in Transnational Corporations and Transnational Governance, 2015, pp 97-111 from Palgrave Macmillan

Abstract: Abstract At some time during their lives, approximately 10–15 per cent of the people in the world will experience significant problems related to gastric acid secretion, with duodenal ulcers being the most common affliction. In 1988, the Swedish pharmaceutical group Astra (now AstraZeneca) introduced a new type of drug, called Losec, which revolutionized the treatment of ulcers. By 1991, 8.9 million patients had been treated with Losec, and the product was marketed all over the world. Losec became one of the most sold drugs in history (Johanson & Vahlne, 1993).

Keywords: Innovation Process; Multinational Corporation; Strategic Management Journal; Bounded Rationality; Transnational Corporation (search for similar items in EconPapers)
Date: 2015
References: Add references at CitEc
Citations:

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:pal:palchp:978-1-137-46769-0_4

Ordering information: This item can be ordered from
http://www.palgrave.com/9781137467690

DOI: 10.1057/9781137467690_4

Access Statistics for this chapter

More chapters in Palgrave Macmillan Books from Palgrave Macmillan
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().